bioAffinity Technologies, Inc. functions as an emerging entity focused on developing innovative solutions for the critical need in non-intrusive, early cancer detection and therapeutic interventions. The firm constructs distinctive in-vitro diagnostic instruments and targeted cancer treatments, employing cutting-edge technology engineered to specifically identify and attack cancerous cells. This company was established on March 26, 2014, with its principal offices situated in San Antonio, Texas.